Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes
Vissia Viglietta, … , Tihamer Orban, David A. Hafler
Vissia Viglietta, … , Tihamer Orban, David A. Hafler
Published June 1, 2002
Citation Information: J Clin Invest. 2002;109(11):1511-1511. https://doi.org/10.1172/JCI14114C1.
View: Text | PDF | Amended Article
Corrigendum Immunology

GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes

  • Text
  • PDF
Abstract

Authors

Vissia Viglietta, Sally C. Kent, Tihamer Orban, David A. Hafler

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Response to GAD65 in individual type 1 diabetes patients and normal cont...
Response to GAD65 in individual type 1 diabetes patients and normal control subjects with blocking costimulatory signals. PBMCs from type 1 diabetes patients and normal control subjects were cultured with different concentrations of GAD65 (0.1-20 μg/ml) or TT (0.01-1 Lf/ml) in the presence or absence of anti-CD28 F(ab′) fragments. After 5 days of culture, rhIL-2 was added to each of ten replicates established for each antigen concentration with or without blocking Ab’s. After an additional 5-7 days of culture, supernatants were collected for cytokine detection, and proliferation was assessed by [3H]thymidine incorporation. (a) T cell proliferation in 19 separate experiments. Each symbol represents the mean thymidine uptake of ten replicate cultures ± SE, stimulated only with the antigen (open squares) or with antigen plus anti-CD28 F(ab′) fragment (filled squares). T cells from both patients and controls proliferated in response to GAD65, and blockade of CD28 costimulatory pathway inhibited GAD65 proliferation and (b and c) cytokine secretion in healthy subjects but not in patients with type 1 diabetes. A summary of all the new-onset patients and controls is shown in Figure 2. (d) Proliferation and cytokine secretion in five long-term diabetic patients.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts